MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2835-2842

  Wong, Stanley Thian Sze ^a   Zhang, Xiao Qin ^a   Zhuang, James Tin Fong ^a   Chan, Hin Lun ^a   Li, Chi Han ^a   Leung, Gilberto Ka Kit ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chemoresistance; Epigenetics; Glioblastoma; MicroRNA; Temozolomide

Indexed keywords

AMI 17000; ANTINEOPLASTIC AGENT; ANTISENSE MICRORNA 21 OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; MICRORNA 21; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CLONE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EXPOSURE; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; TUMOR CELL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DACARBAZINE; GENE THERAPY; GLIOBLASTOMA; HUMANS; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84865681797     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
2. Koukourakis GV, Kouloulias V, Zacharias G, Papadimitriou C, Pantelakos P, Maravelis G, Fotineas A, Beli I, Chaldeopoulos D and Kouvaris J: Temozolomide with radiation therapy in high-grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules 14: 1561-1577, 2009.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG and Mirimanoff RO: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 : 459-466, 2009.
4. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S and Kokkinakis DM: Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8: 2725-2734, 2002. (Pubitemid 34856362)
5. Tentori L and Graziani G: Recent approaches to improve the antitumor efficacy of temozolomide. Curr Med Chem 16: 245-257, 2009.
6. Moore LM and Zhang W: Targeting miR-21 in glioma: a small RNA with big potential. Expert Opin Ther Targets 14: 1247-1257, 2010.
7. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
8. Fernandez LA, Northcott PA, Taylor MD and Kenney AM: Normal and oncogenic roles for microRNAs in the developing brain. Cell Cycle 8: 4049-4054, 2009.
9. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE and Reifenberger G: Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20: 539-550, 2010.
10. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM and Farace MG: Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334: 1351-1358, 2005. (Pubitemid 41074723)
11. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF, Maio F, Cama A, Germano A, Vita G and Tomasello F: miR-21 and 221 upregulation and miR-181b down-regulation in human grade II-IV astrocytic tumors. J Neurooncol 93: 325-332, 2009.
12. Chan JA, Krichevsky AM and Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033, 2005. (Pubitemid 40994386)
13. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS and Krichevsky AM: MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 28 : 5369-5380, 2008.
14. Papagiannakopoulos T, Shapiro A and Kosik KS: MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68 : 8164-8172, 2008.
15. Shi L, Chen J, Yang J, Pan T, Zhang S and Wang Z: miR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing BAX/BCL-2 ratio and caspase-3 activity. Brain Res 1352: 255-264, 2010.
16. Shi L, Zhang S, Feng K, Wu F, Wan Y, Wang Z, Zhang J, Wang Y, Yan W, Fu Z and You Y: MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol 40 : 119-129, 2012.
17. Sun S, Wong TS, Zhang XQ, Pu JK, Lee NP, Day PJ, Ng GK, Lui WM and Leung GK: Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines. J Neurooncol 107: 89-100, 2012.
18. Lu C and Shervington A: Chemoresistance in gliomas. Mol Cell Biochem 312: 71-80, 2008.
19. Chakravarti A and Palanichamy K: Overcoming therapeutic resistance in malignant gliomas: current practices and future directions. Cancer Treat Res 139: 173-189, 2008.
20. Cheng L, Bao S and Rich JN: Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 80: 654-665, 2010.
21. Huang GL, Zhang XH, Guo GL, Huang KT, Yang KY, Shen X, You J and Hu XQ: Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 21: 673-679, 2009.
22. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54: 1696-1704, 2008.
23. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21) post-transcriptionally down-regulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27 : 2128-2136, 2008. (Pubitemid 351485639)
24. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658, 2007. (Pubitemid 47187346)
25. Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328-14336, 2007. (Pubitemid 47100416)
26. Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W, Shao N, Qu H, Yang C, Zhang Y, Wang Q, Wang R, Zen K, Zhang CY, Zhang J and Yang Y: The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 46: 1640-1649, 2010.
27. Kurashige J, Kamohara H, Watanabe M, Tanaka Y, Kinoshita K, Saito S, Hiyoshi Y, Iwatsuki M, Baba Y and Baba H: Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol, 2012 Feb 21. doi: 10.1002/jso.23064. [Epub ahead of print].
28. Ren Y, Zhou X, Mei M, Yuan XB, Han L, Wang GX, Jia ZF, Xu P, Pu PY and Kang CS: MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 10: 27, 2010.
29. Zhou X, Zhang J, Jia Q, Ren Y, Wang Y, Shi L, Liu N, Wang G, Pu P, You Y and Kang C: Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3. Oncol Rep 24: 195-201, 2010.
30. Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, Wang B, Wang G, Jia Z, Pu P, Zhang W and Kang C: Down-regulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest 90: 144-155, 2010.
31. Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E, Smrcka M, Svoboda M, Dolezalova H, Novakova J, Valik D, Vyzula R and Michalek J: MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 57: 264-269, 2010.
32. Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K, Nagata I and Yamashita S: miR-195, miR-455-3p and miR-10a(&z.ast;) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 296: 241-248, 2010.
33. Katakowski M, Buller B, Wang X, Rogers T and Chopp M: Functional microRNA is transferred between glioma cells. Cancer Res 70: 8259-8263, 2010.
34. Allard E, Passirani C and Benoit JP: Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 30: 2302-2318, 2009.
35. Klinghoffer RA, Magnus J, Schelter J, Mehaffey M, Coleman C and Cleary MA: Reduced seed region-based off-target activity with lentivirus-mediated RNAi. RNA 16: 879-884, 2010.
36. Purow B: The elephant in the room: Do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma? J Neurooncol 103: 429-436, 2011.